Washington University ID-CRU conducts research in several areas such as: HIV treatment, HIV prevention, hepatitis, fungal infections, sexually transmitted diseases, the COVID-19 virus as well as various other general vaccine studies. No matter your health, age, or gender we may have a study for YOU. Here are a few of the studies for which we are currently enrolling.
HIV Clinical Trials
EBT-101
Participants in this study must have an undetectable viral load while on their antiretroviral therapy (ART). The investigational product is called EBT-101, a genome editing treatment. It is given as a single intravenous (IV) infusion.
The sponsor is doing this study to see if EBT-101 will cut out the HIV DNA in cells that are currently being suppressed with ART therapy.
Participants must meet these requirements (among others):
- Males (sex at birth) age 18 – 60 years on stable ART therapy for at least 2 years
- Have no other chronic illnesses
- Are willing and able to attend weekly and sometimes daily visits to your doctor
- Are willing to pause ART therapy, if eligible, for analytic treatment interruption (ATI).
Study Procedures include:
- One IV dose of EBT 101
- Daily visits for the first 14 days after dosing and weekly visits through week 48. Then, follow-up visits twice yearly for the next five years and yearly visits for the following 10 year
The ID-CRU has many more ongoing studies. Also, transportation and monetary compensation are often provided.
These studies can be a great way to move science and healthcare forward while providing you with a chance to become engaged and informed. You will receive quality healthcare, individualized support and an opportunity to make a difference. Anyone can participate and we want you.
If interested please contact us to find out which studies are right for you, call us at 314-454-0058 or email at idcru@wustl.edu.